- Exchange: Berlin
- Sector: Consumer, Non-cyclical
- Industry: Healthcare-Products
- Sub-Industry: Diagnostic Kits
Snapshot for Quidel Corp (QL1)
| Open: | 17.515 | Day's Range: | 17.410 - 17.733 | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | 17.692 | 52wk Range: | 11.690 - 18.690 | 1-Yr Rtn: | +42.66% |
Key Statistics for QL1
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | 36.5135 |
| Relative P/E vs. DAX | - |
| Earnings Per Share (USD) (ttm) | - |
| Est. EPS (USD) (12/2013) | 0.6230 |
| Est. PEG Ratio | 1.5980 |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 0 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/25/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for QL1
Company Profile & Key Executives for QL1
Quidel Corporation discovers, develops, manufactures, and markets rapid diagnostic products for point-of-care detection of human medical conditions and illnesses. The Company's products provide diagnoses for acute and chronic conditions in the areas of women's health and infectious diseases. Quidel's products are sold to professionals and to consumers.
| Douglas C BryantPresident/CEO | Randall J StewardChief Financial Officer |
| Timothy T StenzelChief Scientific Officer | Robert Joseph BujarskiSenior VP:Bus Dev/Gen Cnsl |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
QL1 News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page